logo-loader

Cynata Therapeutics to reveal details on clinical trial

Published: 01:30 15 May 2017 BST

1-Imperial-Innovations-(2)
Cynata is a stem cell and regenerative medicine company

Cynata Therapeutics (ASX:CYP) has some very interesting news on the horizon, with the company entering an ASX trading halt pending an update on its Phase 1 clinical trial.

The halt will remain in place until the opening of trade on Wednesday 17th May 2017, or earlier if an announcement will be made to the market.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

26 minutes ago